144 related articles for article (PubMed ID: 22571484)
21. [Genetic polymorphism of the CYP2C subfamily].
Chiba K
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
[TBL] [Abstract][Full Text] [Related]
22. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment.
Bu HZ
Curr Drug Metab; 2006 Apr; 7(3):231-49. PubMed ID: 16611019
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
Br J Clin Pharmacol; 2001 Oct; 52(4):349-55. PubMed ID: 11678778
[TBL] [Abstract][Full Text] [Related]
24. Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biol Pharm Bull; 2016; 39(11):1748-1759. PubMed ID: 27803446
[TBL] [Abstract][Full Text] [Related]
25. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
26. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
[TBL] [Abstract][Full Text] [Related]
27. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
28. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
[TBL] [Abstract][Full Text] [Related]
29. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
[TBL] [Abstract][Full Text] [Related]
30. The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes.
Chou YC; Chung YT; Liu TY; Wang SY; Chau GY; Chi CW; Soucek P; Krausz KW; Gelboin HV; Lee CH; Ueng YF
J Pharm Sci; 2010 Feb; 99(2):1063-77. PubMed ID: 19593786
[TBL] [Abstract][Full Text] [Related]
31. Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors.
Hosaka S; Murayama N; Satsukawa M; Uehara S; Shimizu M; Iwasaki K; Iwano S; Uno Y; Yamazaki H
Biopharm Drug Dispos; 2016 Jul; 37(5):310-3. PubMed ID: 26581561
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms.
Subrahmanyam V; Renwick AB; Walters DG; Price RJ; Tonelli AP; Lake BG
Xenobiotica; 2002 Jun; 32(6):521-34. PubMed ID: 12160484
[TBL] [Abstract][Full Text] [Related]
33. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
34. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
35. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.
Scheer N; Kapelyukh Y; Chatham L; Rode A; Buechel S; Wolf CR
Mol Pharmacol; 2012 Dec; 82(6):1022-9. PubMed ID: 22918969
[TBL] [Abstract][Full Text] [Related]
36. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
37. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes.
Lundblad MS; Stark K; Eliasson E; Oliw E; Rane A
Biochem Biophys Res Commun; 2005 Feb; 327(4):1052-7. PubMed ID: 15652503
[TBL] [Abstract][Full Text] [Related]
38. Analyses of CYP2C in porcine microsomes.
Skaanild MT; Friis C
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):487-92. PubMed ID: 18803635
[TBL] [Abstract][Full Text] [Related]
39. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.
Lewis DF
Biochem Pharmacol; 2000 Aug; 60(3):293-306. PubMed ID: 10856424
[TBL] [Abstract][Full Text] [Related]
40. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
